Intracranial AAV-IFN-b gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model

Molecular Oncology

Volumn 11, Issue 2, 2017, Pages 180-193

  Guhasarkar, Dwijit ^a   Neiswender, James ^a   Su, Qin ^a   Gao, Guangping ^a   Sena Esteves, Miguel ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

adeno associated virus; glioblastoma; interferon beta; intracranial; syngeneic; xenograft

Indexed keywords

BETA INTERFERON;

ANIMAL; BIOSYNTHESIS; BRAIN TUMOR; DEPENDOPARVOVIRUS; DRUG SCREENING; GENE THERAPY; GENETICS; GLIOBLASTOMA; HUMAN; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DEPENDOVIRUS; GENETIC THERAPY; GLIOBLASTOMA; HUMANS; INTERFERON-BETA; MALE; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85030229336     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1002/1878-0261.12020     Document Type: Article

References (36)

1. Buchwalder PA, Buclin T, Trinchard I, Munafo A and Biollaz J (2000) Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 20, 857–866.
2. Chtarto A, Bender HU, Hanemann CO, Kemp T, Lehtonen E, Levivier M, Brotchi J, Velu T and Tenenbaum L (2003) Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther 10, 84–94.
3. Denbo JW, Williams RF, Orr WS, Sims TL, Ng CY, Zhou J, Spence Y, Morton CL, Nathwani AC, Duntsch C et al. (2011) Continuous local delivery of interferon-beta stabilizes tumor vasculature in an orthotopic glioblastoma xenograft resection model. Surgery 150,497–504.
4. GuhaSarkar D, Su Q, Gao G and Sena-Esteves M (2016) Systemic AAV9-IFN-b gene delivery treats highly invasive glioblastoma. Neuro Oncol 18, 1508–1518.
5. Hambardzumyan D, Gutmann DH and Kettenmann H (2016) The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19, 20–27.
6. Happold C, Roth P, Silginer M, Florea AM, Lamszus K, Frei K, Deenen R, Reifenberger G and Weller M (2014) Interferon-beta induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Mol Cancer Ther 13, 948–961.
7. Harari D, Abramovich R, Zozulya A, Smith P, Pouly S, Koster M, Hauser H and Schreiber G (2014) Bridging the species divide: transgenic mice humanized for type-I interferon response. PLoS ONE 9, e84259.
8. Hottinger AF, Stupp R and Homicsko K (2014) Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer 33, 32–39.
9. Juang SH, Wei SJ, Hung YM, Hsu CY, Yang DM, Liu KJ, Chen WS and Yang WK (2004) IFN-beta induces caspase-mediated apoptosis by disrupting mitochondria in human advanced stage colon cancer cell lines. J Interferon Cytokine Res 24, 231–243.
10. Kase S, Kubota T, Watanabe M, Furukawa T, Tanino H, Ishibiki K, Teramoto T and Kitajima M (1993) Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Anticancer Res 13, 369–373.
11. Kawanokuchi J, Mizuno T, Kato H, Mitsuma N and Suzumura A (2004) Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology 46, 734–742.
12. Kaynor C, Xin M, Wakefield J, Barsoum J and Qin XQ (2002) Direct evidence that IFN-beta functions as a tumor-suppressor protein. J Interferon Cytokine Res 22, 1089–1098.
13. Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, Enger PO, Zimmer J and Chekenya M (2013) Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol 264, 71–83.
14. Li W and Graeber MB (2012) The molecular profile of microglia under the influence of glioma. Neuro Oncol 14, 958–978.
15. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97–109.
16. Lukashchuk V, Lewis KE, Coldicott I, Grierson AJ and Azzouz M (2016) AAV9-mediated central nervous system-targeted gene delivery via cisterna magna route in mice. Mol Ther Methods Clin Dev 3, 15055.
17. Maguire CA, Meijer DH, LeRoy SG, Tierney LA, Broekman ML, Costa FF, Breakefield XO, Stemmer-Rachamimov A and Sena-Esteves M (2008) Preventing growth of brain tumors by creating a zone of resistance. Mol Ther 16, 1695–1702.
18. Mao Y, Yao Y, Zhang LW, Lu YC, Chen ZP, Zhang JM, Qi ST, You C, Wang RZ, Yang SY et al. (2015) Does early postsurgical temozolomide plus concomitant radiochemotherapy regimen have any benefit in newly-diagnosed glioblastoma patients? A multi-center, randomized, parallel, open-label, phase II clinical trial. Chin Med J (Engl) 128, 2751–2758.
19. McCarty DM (2008) Self-complementary AAV vectors; advances and applications. Mol Ther 16, 1648–1656.
20. Meijer DH, Maguire CA, LeRoy SG and Sena-Esteves M (2009) Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther 16, 664–671.
21. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K and Wakabayashi T (2011) Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer 117, 1721–1730.
22. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M and Stupp R (2011) Current concepts and management of glioblastoma. Ann Neurol 70, 9–21.
23. Preusser M, Lim M, Hafler DA, Reardon DA and Sampson JH (2015) Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 11, 504–514.
24. Ruan H, Su H, Hu L, Lamborn KR, Kan YW and Deen DF (2001) A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 3, 255–263.
25. Schneider WM, Chevillotte MD and Rice CM (2014) Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32, 513–545.
26. See AP, Parker JJ and Waziri A (2015) The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression. J Neurooncol 123, 405–412.
27. Streck CJ, Dickson PV, Ng CY, Zhou J, Hall MM, Gray JT, Nathwani AC and Davidoff AM (2006) Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Ther 13, 99–106.
28. Streck CJ, Ng CY, Zhang Y, Zhou J, Nathwani AC and Davidoff AM (2005) Interferon-mediated anti-angiogenic therapy for neuroblastoma. Cancer Lett 228, 163–170.
29. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459–466.
30. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987–996.
31. Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC et al. (2009) Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69, 3472–3481.
32. Wolpert F, Happold C, Reifenberger G, Florea AM, Deenen R, Roth P, Neidert MC, Lamszus K, Westphal M, Weller M et al. (2015) Interferon-beta modulates the innate immune response against glioblastoma initiating cells. PLoS ONE 10, e0139603.
33. Wu C, Lin J, Hong M, Choudhury Y, Balani P, Leung D, Dang LH, Zhao Y, Zeng J and Wang S (2009) Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy. Mol Ther 17, 2058–2066.
34. Xiao HB, Zhou WY, Chen XF, Mei J, Lv ZW, Ding FB, Li GQ, Zhong H and Bao CR (2012) Interferon-beta efficiently inhibited endothelial progenitor cell-induced tumor angiogenesis. Gene Ther 19, 1030–1034.
35. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y and Fu YX (2014) Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25, 37–48.
36. Yawata T, Maeda Y, Okiku M, Ishida E, Ikenaka K and Shimizu K (2011) Identification and functional characterization of glioma-specific promoters and their application in suicide gene therapy. J Neurooncol 104, 497–507.